Cargando…

Meta-analysis of randomized phase II trials to inform subsequent phase III decisions

BACKGROUND: If multiple Phase II randomized trials exist then meta-analysis is favorable to increase statistical power and summarize the existing evidence about an intervention's effect in order to help inform Phase III decisions. We consider some statistical issues for meta-analysis of Phase I...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burke, Danielle L, Billingham, Lucinda J, Girling, Alan J, Riley, Richard D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4162965/ https://www.ncbi.nlm.nih.gov/pubmed/25187348 http://dx.doi.org/10.1186/1745-6215-15-346

Ejemplares similares

Using meta-analysis of Phase II trials to predict Phase III trial results
por: Burke, Danielle, et al.
Publicado: (2013)

Efficacy gap between phase II and subsequent phase III studies in oncology
por: Vreman, Rick A., et al.
Publicado: (2020)

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
por: Yap, Christina, et al.
Publicado: (2011)

Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia
por: Yap, Christina, et al.
Publicado: (2013)

Locally advanced breast cancer: report of phase II study and subsequent phase III trial.
por: Rodger, A., et al.
Publicado: (1992)

Decision Making in the PICU: An Examination of Factors Influencing Participation Decisions in Phase III Randomized Clinical Trials
por: Slosky, Laura E., et al.
Publicado: (2014)

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations
por: Hubner, Richard A., et al.
Publicado: (2011)

Analysis of early phase and subsequent phase III stroke studies of neuroprotectants: outcomes and predictors for success
por: Minnerup, Jens, et al.
Publicado: (2014)

Reviewing the evidence supporting predictive biomarkers in European medicines agency indications and contraindications using visual plots
por: Malottki, Kinga, et al.
Publicado: (2015)

Challenges in the development of prognostic models utilising clinical trials data
por: Snell, Kym, et al.
Publicado: (2013)

Laparoscopic Radiofrequency Fibroid Ablation: Phase II and Phase III Results
por: Galen, Donald I., et al.
Publicado: (2014)

Lasmiditan abortive therapy for episodic migraine in Phase II/III randomized clinical trials: A meta-analysis
por: Ahsan, Marya, et al.
Publicado: (2022)

Implementation of adaptive dose-finding designs in two early phase haematological trials: clinical, operational, and methodological challenges
por: Yap, Christina, et al.
Publicado: (2013)

Beta-hydroxy beta-methylbutyrate/arginine/glutamine (HMB/Arg/Gln) supplementation to improve the management of cachexia in patients with advanced lung cancer: an open-label, multicentre, randomised, controlled phase II trial (NOURISH)
por: Pascoe, Jennifer, et al.
Publicado: (2021)

Using phase II data for the analysis of phase III studies: An application in rare diseases
por: Wandel, Simon, et al.
Publicado: (2017)

Transactivation of Genes Encoding for Phase II Enzymes and Phase III Transporters by Phytochemical Antioxidants
por: Yang, Yoon Mee, et al.
Publicado: (2010)

Inefficiencies in phase II to phase III transition impeding successful drug development in glioblastoma
por: Balasubramanian, Adithya, et al.
Publicado: (2020)

Optimal designs for phase II/III drug development programs including methods for discounting of phase II results
por: Erdmann, Stella, et al.
Publicado: (2020)

An adaptive seamless phase II/III clinical trial design incorporating short-term endpoint information
por: Stallard, Nigel
Publicado: (2011)

Analysis of phase II methodologies for single-arm clinical trials with multiple endpoints in rare cancers: An example in Ewing’s sarcoma
por: Dutton, P, et al.
Publicado: (2016)

Omadacycline for treatment of acute bacterial infections: a meta-analysis of phase II/III trials
por: Lin, Fei, et al.
Publicado: (2023)

Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2016)

Lipid profile and effect of statin treatment in pooled phase II and phase III baricitinib studies
por: Taylor, Peter C, et al.
Publicado: (2018)

The hypoxia marker CAIX is prognostic in the UK phase III VorteX-Biobank cohort: an important resource for translational research in soft tissue sarcoma
por: Forker, Laura, et al.
Publicado: (2018)

Minimally invasive adrenalectomy: a comprehensive systematic review and network meta-analysis of phase II/III randomized clinical controlled trials
por: Alberici, Laura, et al.
Publicado: (2022)

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials
por: Bowling, Gartrell C., et al.
Publicado: (2023)

Gradeability and Reproducibility of Geographic Atrophy Measurement in GATHER-1, a Phase II/III Randomized Interventional Trial
por: Li, Angela S., et al.
Publicado: (2023)

Stratified medicine in practice: review of predictive biomarkers in European Medicines Agency (EMA) indications
por: Malottki, Kinga, et al.
Publicado: (2011)

Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strata
por: Woll, Penella J., et al.
Publicado: (2023)

Biomarker-Guided Non-Adaptive Trial Designs in Phase II and Phase III: A Methodological Review
por: Antoniou, Miranta, et al.
Publicado: (2017)

Imposing Phase II and Phase III Clinical Trials of Targeted Drugs for Glioblastoma: Current Status and Progress
por: Wang, Yaning, et al.
Publicado: (2021)

Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase IIa open‐label trial and subsequent phase III open‐label extension
por: Cork, M.J., et al.
Publicado: (2019)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
por: Bhagavathula, Akshaya Srikanth, et al.
Publicado: (2021)

Information on the Implementation of Phase II of the Budget and Accounting Reform
Publicado: (1991)

Hepatic profile analyses of tipranavir in Phase II and III clinical trials
por: Mikl, Jaromir, et al.
Publicado: (2009)

Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies
por: Luo, Xiaoping, et al.
Publicado: (2017)

Problems of variable biomarker evaluation in stratified medicine research—A case study of ERCC1 in non-small-cell lung cancer
por: Malottki, Kinga, et al.
Publicado: (2016)

Safety of tralokinumab in adult patients with moderate‐to‐severe atopic dermatitis: pooled analysis of five randomized, double‐blind, placebo‐controlled phase II and phase III trials
por: Simpson, Eric L., et al.
Publicado: (2022)

Evaluation of methods to adjust for treatment switching in clinical trials
por: Fox, Richard, et al.
Publicado: (2011)

Correct usage, ease of use, and preference of two dry powder inhalers in patients with COPD: analysis of five phase III, randomized trials
por: Riley, John H, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tduela505jt0mshqhdi01kqpif